@article{zarin_trial_2005,
	title = {Trial Registration at {ClinicalTrials}.gov between May and October 2005},
	volume = {353},
	issn = {0028-4793},
	url = {http://www.nejm.org/doi/full/10.1056/NEJMsa053234},
	doi = {10.1056/NEJMsa053234},
	abstract = {Concern about previously undisclosed safety problems with drugs such as paroxetine (Paxil, {GlaxoSmithKline}) and rofecoxib (Vioxx, Merck) has increased the public's desire for more complete information about clinical research studies.1,2 The provision of basic information about clinical trial protocols in a publicly accessible registry and the public identification of all trials, whether or not their results are subsequently published, have been advocated as ways to address this issue.3–6 Numerous groups have called for comprehensive registration by issuing statements or convening meetings to discuss policy and implementation details.7–15 In the United States, the Food and Drug Administration ({FDA}) . . .},
	pages = {2779--2787},
	number = {26},
	journaltitle = {New England Journal of Medicine},
	author = {Zarin, Deborah A. and Tse, Tony and Ide, Nicholas C.},
	urldate = {2013-01-28},
	date = {2005},
	pmid = {16382064}
}

